During the past decade, Kaluga Regional Clinical Hospital conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Kaluga Regional Clinical Hospital" are "AML Arising From Myelodysplastic Syndrome (MDS)" (1 trials), "Leukemia, Myeloid, Acute" (1 trials), "Multiple Myeloma" (1 trials), "Newly Diagnosed Acute Myeloid Leukemia (AML)" (1 trials) and "Pulmonary Disease, Chronic Obstructive" (1 trials). Many other conditions were trialed in "Kaluga Regional Clinical Hospital" in a lesser frequency.

Most popular intervention types in "Kaluga Regional Clinical Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "AG-120" (1 trials), "Azacitidine" (1 trials), "Placebo" (1 trials) and "Spiolto® Respimat®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kaluga Regional Clinical Hospital" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Kaluga Regional Clinical Hospital". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Kaluga Regional Clinical Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kaluga Regional Clinical Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".